Salarius Pharmaceuticals, Inc. (SLRX) 10-Year Financial Performance & Capital Metrics

SLRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutSalarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.Show more

Revenue $0
EBITDA -$6M +55.5%
Net Income -$6M +55.5%
EPS (Diluted) -86.85 -152268.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -164.02% -2.5%
ROIC -
Debt/Equity 0.15 +167.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 70.5% through buybacks
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.22%

EPS CAGR

10Y-

5Y-

3Y-

TTM61.9%

ROCE

10Y Avg-94.69%

5Y Avg-110.52%

3Y Avg-154.31%

Latest-168.68%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.01M	1.27M	838.14K	3.47M	5.23M	0	0	0	0
Revenue Growth %	-	-	0.26%	-0.34%	3.13%	0.51%	-1%	-	-	-
Cost of Goods Sold+	49.88K	662.75K	506.53K	430.75K	0	0	0	0	0	0
COGS % of Revenue	-	0.66%	0.4%	0.51%	-	-	-	-	-	-
Gross Profit+	-49.88K	347.92K	767.97K	407.39K	3.47M	5.23M	0	0	0	0
Gross Margin %	-	0.34%	0.6%	0.49%	1%	1%	-	-	-	-
Gross Profit Growth %	-	7.97%	1.21%	-0.47%	7.51%	0.51%	-1%	-	-	-
Operating Expenses+	29.21M	40.23M	35.49M	22.48M	11.73M	13.02M	12.81M	31.84M	12.89M	5.73M
OpEx % of Revenue	-	39.81%	27.85%	26.82%	3.39%	2.49%	-	-	-	-
Selling, General & Admin	16.46M	19.86M	18.5M	10.57M	7.71M	6.11M	6.1M	7.14M	5.72M	4.96M
SG&A % of Revenue	-	19.65%	14.52%	12.62%	2.23%	1.17%	-	-	-	-
Research & Development	12.75M	20.38M	16.99M	11.91M	4.02M	6.91M	8.55M	15.84M	7.17M	770.03K
R&D % of Revenue	-	20.16%	13.33%	14.21%	1.16%	1.32%	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	-1.84M	8.87M	0	0
Operating Income+	-29.21M	-39.89M	-34.73M	-22.07M	-8.27M	-7.79M	-12.81M	-31.84M	-12.89M	-5.73M
Operating Margin %	-	-39.47%	-27.25%	-26.34%	-2.39%	-1.49%	-	-	-	-
Operating Income Growth %	-	-0.37%	0.13%	0.36%	0.63%	0.06%	-0.65%	-1.49%	0.6%	0.56%
EBITDA+	-29.16M	-39.61M	-34.4M	-21.85M	-8.14M	-7.77M	-12.79M	-31.83M	-12.88M	-5.73M
EBITDA Margin %	-	-39.19%	-26.99%	-26.06%	-2.35%	-1.48%	-	-	-	-
EBITDA Growth %	-	-0.36%	0.13%	0.36%	0.63%	0.05%	-0.65%	-1.49%	0.6%	0.56%
D&A (Non-Cash Add-back)	49.88K	277.23K	324.55K	228.16K	127.41K	18.06K	19.18K	6.68K	10.05K	4.42K
EBIT	-29.14M	-39.89M	-34.73M	-22.07M	-8.26M	-7.61M	-12.81M	-22.98M	-12.89M	-5.73M
Net Interest Income+	0	393.11K	291.96K	152.01K	15.65K	-3.05K	0	219	352.25K	158.54K
Interest Income	0	393.11K	291.96K	152.01K	15.65K	0	0	219	352.25K	158.54K
Interest Expense	0	0	0	0	0	3.05K	0	0	0	0
Other Income/Expense	72K	393.11K	291.96K	152.01K	1.33M	434.09K	44.69K	233.18K	352.25K	158.54K
Pretax Income+	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Pretax Margin %	-	-39.08%	-27.02%	-26.16%	-2%	-1.4%	-	-	-	-
Income Tax+	630	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Net Margin %	-	-39.08%	-27.02%	-26.16%	-2%	-1.4%	-	-	-	-
Net Income Growth %	-	-0.36%	0.13%	0.36%	0.68%	-0.06%	-0.74%	-1.48%	0.6%	0.56%
Net Income (Continuing)	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Discontinued Operations	0	0	0	0	1.83K	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19468.80	-182250.00	-149250.00	-91500.00	-6360.00	-1500.00	-930.00	-221.55	-0.06	-86.85
EPS Growth %	-	-8.36%	0.18%	0.39%	0.93%	0.76%	0.38%	0.76%	1%	-1522.68%
EPS (Basic)	-19468.80	-182250.00	-149250.00	-91500.00	-6360.00	-1500.00	-930.00	-221.55	-0.06	-86.85
Diluted Shares Outstanding	1.5K	1.09M	1.16M	1.21M	1.09K	5.22K	13.86K	142.34K	218.73K	64.47K
Basic Shares Outstanding	1.5K	1.09M	1.16M	1.21M	1.09K	5.22K	13.8K	142.34K	218.73K	64.47K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	92.25M	62.47M	34.54M	10.32M	4.69M	15.8M	30.16M	14.52M	6.52M	2.99M
Cash & Short-Term Investments	91.34M	61.07M	33.32M	9.83M	3.74M	11.12M	29.21M	12.11M	5.9M	2.43M
Cash Only	66.69M	22.42M	19.19M	9.83M	3.74M	11.12M	29.21M	12.11M	5.9M	2.43M
Short-Term Investments	24.65M	38.66M	14.13M	0	0	0	0	0	0	0
Accounts Receivable	0	12.18K	10.38K	9.94K	0	3.86M	0	1.61M	0	0
Days Sales Outstanding	-	4.4	2.97	4.33	-	268.94	-	-	-	-
Inventory	0	454.13K	431.89K	186.92K	0	0	0	0	0	0
Days Inventory Outstanding	-	250.11	311.22	158.39	-	-	-	-	-	-
Other Current Assets	0	0	767.56K	249.09K	0	137.78K	172.99K	167.58K	151.27K	221.58K
Total Non-Current Assets+	2.82M	747.71K	457.63K	74.46K	9.2M	9.14M	10.67M	130.5K	66.85K	35.41K
Property, Plant & Equipment	382.44K	556.32K	331.04K	74K	25.02K	22.64K	7.88K	0	0	0
Fixed Asset Turnover	-	1.82x	3.85x	11.33x	138.51x	231.16x	-	-	-	-
Goodwill	0	0	0	0	8.87M	8.87M	8.87M	0	0	0
Intangible Assets	0	0	66.4K	0	0	0	0	0	0	0
Long-Term Investments	2.31M	0	0	0	0	0	1.61M	0	0	0
Other Non-Current Assets	126.83K	191.4K	60.2K	460	308.67K	247.11K	185.99K	130.5K	66.85K	35.41K
Total Assets+	95.07M	63.21M	34.99M	10.39M	13.89M	24.93M	40.83M	14.65M	6.59M	3.02M
Asset Turnover	-	0.02x	0.04x	0.08x	0.25x	0.21x	-	-	-	-
Asset Growth %	-	-0.34%	-0.45%	-0.7%	0.34%	0.79%	0.64%	-0.64%	-0.55%	-0.54%
Total Current Liabilities+	2.85M	3.89M	5.85M	5.02M	3.31M	2.77M	2.11M	4.27M	1.3M	1.51M
Accounts Payable	875.65K	1.19M	2M	342.53K	1.79M	1.85M	1.54M	2.86M	602.85K	936.99K
Days Payables Outstanding	6.41K	656.58	1.44K	290.25	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	502.33K	477.03K	0	0	289.64K	221.87K
Deferred Revenue (Current)	0	88K	72.19K	0	541.7K	0	0	0	0	0
Other Current Liabilities	672.51K	1.16M	2.9M	3.91M	317.76K	59.21K	0	0	0	0
Current Ratio	32.40x	16.06x	5.91x	2.06x	1.42x	5.70x	14.29x	3.40x	5.02x	1.98x
Quick Ratio	32.40x	15.94x	5.83x	2.02x	1.42x	5.70x	14.29x	3.40x	5.02x	1.98x
Cash Conversion Cycle	-	-402.07	-1.13K	-127.53	-	-	-	-	-	-
Total Non-Current Liabilities+	30.03K	8.4K	39.21K	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	30.03K	8.4K	39.21K	0	0	0	0	0	0	0
Total Liabilities	2.88M	3.9M	5.89M	1.11M	3.31M	2.77M	2.11M	4.27M	1.3M	1.51M
Total Debt+	0	0	0	0	502.33K	477.03K	0	0	289.64K	221.87K
Net Debt	-66.69M	-22.42M	-19.19M	-9.83M	-3.24M	-10.64M	-29.21M	-12.11M	-5.61M	-2.21M
Debt / Equity	-	-	-	-	0.05x	0.02x	-	-	0.05x	0.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-2555.41x	-	-	-	-
Total Equity+	92.19M	59.32M	29.11M	9.28M	10.58M	22.16M	38.72M	10.38M	5.29M	1.51M
Equity Growth %	-	-0.36%	-0.51%	-0.68%	0.14%	1.09%	0.75%	-0.73%	-0.49%	-0.71%
Book Value per Share	61286.57	54.54	25.17	7.69	9663.05	4246.01	2794.36	72.96	24.17	23.45
Total Shareholders' Equity	92.19M	59.32M	29.11M	9.28M	10.58M	22.16M	38.72M	10.38M	5.29M	1.51M
Common Stock	1.57K	1.68K	1.78K	1.81K	451	2.38K	4.52K	225	393	144
Retained Earnings	-37.15M	-76.65M	-111.08M	-132.96M	-12.08M	-19.43M	-32.2M	-63.81M	-76.35M	-81.92M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-24.65K	-1.61K	-1.25K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.75M	-32.05M	-27.72M	-23.6M	-11.58M	-10.31M	-10.2M	-17.6M	-12.85M	-4.53M
Operating CF Margin %	-	-31.71%	-21.75%	-28.16%	-3.34%	-1.97%	-	-	-	-
Operating CF Growth %	-	-0.54%	0.14%	0.15%	0.51%	0.11%	0.01%	-0.72%	0.27%	0.65%
Net Income	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Depreciation & Amortization	49.88K	277.23K	324.55K	228.16K	127.41K	18.06K	19.18K	6.68K	10.05K	4.42K
Stock-Based Compensation	6.6M	6.57M	4.22M	1.94M	751.62K	319.39K	559.04K	796.8K	524.84K	273.73K
Deferred Taxes	9.52K	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	4.12K	19.59K	-66.36K	31.85K	-1.31M	-258.55K	-44.69K	10.84M	130K	0
Working Capital Changes	1.73M	571.22K	2.23M	-3.88M	-4.21M	-3.04M	2.03M	2.37M	-968.33K	772.29K
Change in Receivables	0	0	1.8K	7.21K	690	-3.86M	2.25M	0	1.48M	0
Change in Inventory	0	0	22.24K	227.98K	1.17K	0	0	0	0	0
Change in Payables	621.39K	309.44K	819.36K	-1.66M	-519.28K	-2.78K	-310.66K	1.31M	-2.26M	334.14K
Cash from Investing+	-27.27M	-12.24M	24.49M	14.12M	5.61M	-2.6K	0	-1.5M	0	0
Capital Expenditures	-265.62K	-559.38K	-113.5K	0	0	-2.6K	0	0	-3	0
CapEx % of Revenue	-	0.55%	0.09%	-	-	0%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	5.25K	5.34K	4.8K	0	0	0	-1.5M	3	0
Cash from Financing+	80.84M	22.1K	2.63K	118.01K	3.58M	17.69M	28.3M	1.99M	6.64M	1.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-133.59K	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	400K	0	0	118.01K	0	3.87M	1.49M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.01M	-32.61M	-27.84M	-23.6M	-11.58M	-10.31M	-10.2M	-19.1M	-12.85M	-4.53M
FCF Margin %	-	-32.27%	-21.84%	-28.16%	-3.34%	-1.97%	-	-	-	-
FCF Growth %	-	-0.55%	0.15%	0.15%	0.51%	0.11%	0.01%	-0.87%	0.33%	0.65%
FCF per Share	-13967.93	-29.98	-24.07	-19.55	-10575.61	-1976.30	-736.08	-134.15	-58.73	-70.20
FCF Conversion (FCF/Net Income)	0.71x	0.81x	0.81x	1.08x	1.67x	1.40x	0.80x	0.56x	1.02x	0.81x
Interest Paid	0	0	0	0	9.01K	8.66K	1.47K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.61%	-52.13%	-77.88%	-114.21%	-69.84%	-44.91%	-41.94%	-128.73%	-160.07%	-164.02%
Return on Invested Capital (ROIC)	-85.9%	-95.87%	-111.25%	-353.26%	-182.39%	-61.92%	-91.41%	-613.37%	-	-
Gross Margin	-	34.42%	60.26%	48.61%	100%	100%	-	-	-	-
Net Margin	-	-3907.65%	-2701.74%	-2615.57%	-200.18%	-140.49%	-	-	-	-
Debt / Equity	-	-	-	-	0.05x	0.02x	-	-	0.05x	0.15x
Interest Coverage	-	-	-	-	-	-2555.41x	-	-	-	-
FCF Conversion	0.71x	0.81x	0.81x	1.08x	1.67x	1.40x	0.80x	0.56x	1.02x	0.81x
Revenue Growth	-	-	26.11%	-34.24%	313.42%	51.03%	-100%	-	-	-

Revenue by Segment

	2016	2017	2018	2020
Grant, Castration-Resistant Prostate Study	-	-	-	2.6M
Grant, Castration-Resistant Prostate Study Growth	-	-	-	-
Product	-	-	826.51K	-
Product Growth	-	-	-	-
Product and Service, Other	-	-	11.63K	-
Product and Service, Other Growth	-	-	-	-
Consumer Operations	1.01M	1.27M	-	-
Consumer Operations Growth	-	26.11%	-	-
Drug Development	-	-	-	-
Drug Development Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

Salarius Pharmaceuticals, Inc. (SLRX) grew revenue by 0.0% over the past year. Growth has been modest.

Salarius Pharmaceuticals, Inc. (SLRX) reported a net loss of $5.0M for fiscal year 2024.

Dividend & Returns

Salarius Pharmaceuticals, Inc. (SLRX) has a return on equity (ROE) of -164.0%. Negative ROE indicates the company is unprofitable.

Salarius Pharmaceuticals, Inc. (SLRX) had negative free cash flow of $4.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Salarius Pharmaceuticals, Inc. (SLRX) 10-Year Financial Performance & Capital Metrics

SLRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$6M +55.5%
Net Income -$6M +55.5%
EPS (Diluted) -86.85 -152268.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -164.02% -2.5%
ROIC -
Debt/Equity 0.15 +167.9%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 70.5% through buybacks
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-0.22%

EPS CAGR

10Y-

5Y-

3Y-

TTM61.9%

ROCE

10Y Avg-94.69%

5Y Avg-110.52%

3Y Avg-154.31%

Latest-168.68%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	1.01M	1.27M	838.14K	3.47M	5.23M	0	0	0	0
Revenue Growth %	-	-	0.26%	-0.34%	3.13%	0.51%	-1%	-	-	-
Cost of Goods Sold+	49.88K	662.75K	506.53K	430.75K	0	0	0	0	0	0
COGS % of Revenue	-	0.66%	0.4%	0.51%	-	-	-	-	-	-
Gross Profit+	-49.88K	347.92K	767.97K	407.39K	3.47M	5.23M	0	0	0	0
Gross Margin %	-	0.34%	0.6%	0.49%	1%	1%	-	-	-	-
Gross Profit Growth %	-	7.97%	1.21%	-0.47%	7.51%	0.51%	-1%	-	-	-
Operating Expenses+	29.21M	40.23M	35.49M	22.48M	11.73M	13.02M	12.81M	31.84M	12.89M	5.73M
OpEx % of Revenue	-	39.81%	27.85%	26.82%	3.39%	2.49%	-	-	-	-
Selling, General & Admin	16.46M	19.86M	18.5M	10.57M	7.71M	6.11M	6.1M	7.14M	5.72M	4.96M
SG&A % of Revenue	-	19.65%	14.52%	12.62%	2.23%	1.17%	-	-	-	-
Research & Development	12.75M	20.38M	16.99M	11.91M	4.02M	6.91M	8.55M	15.84M	7.17M	770.03K
R&D % of Revenue	-	20.16%	13.33%	14.21%	1.16%	1.32%	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	-1.84M	8.87M	0	0
Operating Income+	-29.21M	-39.89M	-34.73M	-22.07M	-8.27M	-7.79M	-12.81M	-31.84M	-12.89M	-5.73M
Operating Margin %	-	-39.47%	-27.25%	-26.34%	-2.39%	-1.49%	-	-	-	-
Operating Income Growth %	-	-0.37%	0.13%	0.36%	0.63%	0.06%	-0.65%	-1.49%	0.6%	0.56%
EBITDA+	-29.16M	-39.61M	-34.4M	-21.85M	-8.14M	-7.77M	-12.79M	-31.83M	-12.88M	-5.73M
EBITDA Margin %	-	-39.19%	-26.99%	-26.06%	-2.35%	-1.48%	-	-	-	-
EBITDA Growth %	-	-0.36%	0.13%	0.36%	0.63%	0.05%	-0.65%	-1.49%	0.6%	0.56%
D&A (Non-Cash Add-back)	49.88K	277.23K	324.55K	228.16K	127.41K	18.06K	19.18K	6.68K	10.05K	4.42K
EBIT	-29.14M	-39.89M	-34.73M	-22.07M	-8.26M	-7.61M	-12.81M	-22.98M	-12.89M	-5.73M
Net Interest Income+	0	393.11K	291.96K	152.01K	15.65K	-3.05K	0	219	352.25K	158.54K
Interest Income	0	393.11K	291.96K	152.01K	15.65K	0	0	219	352.25K	158.54K
Interest Expense	0	0	0	0	0	3.05K	0	0	0	0
Other Income/Expense	72K	393.11K	291.96K	152.01K	1.33M	434.09K	44.69K	233.18K	352.25K	158.54K
Pretax Income+	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Pretax Margin %	-	-39.08%	-27.02%	-26.16%	-2%	-1.4%	-	-	-	-
Income Tax+	630	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Net Margin %	-	-39.08%	-27.02%	-26.16%	-2%	-1.4%	-	-	-	-
Net Income Growth %	-	-0.36%	0.13%	0.36%	0.68%	-0.06%	-0.74%	-1.48%	0.6%	0.56%
Net Income (Continuing)	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Discontinued Operations	0	0	0	0	1.83K	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-19468.80	-182250.00	-149250.00	-91500.00	-6360.00	-1500.00	-930.00	-221.55	-0.06	-86.85
EPS Growth %	-	-8.36%	0.18%	0.39%	0.93%	0.76%	0.38%	0.76%	1%	-1522.68%
EPS (Basic)	-19468.80	-182250.00	-149250.00	-91500.00	-6360.00	-1500.00	-930.00	-221.55	-0.06	-86.85
Diluted Shares Outstanding	1.5K	1.09M	1.16M	1.21M	1.09K	5.22K	13.86K	142.34K	218.73K	64.47K
Basic Shares Outstanding	1.5K	1.09M	1.16M	1.21M	1.09K	5.22K	13.8K	142.34K	218.73K	64.47K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	92.25M	62.47M	34.54M	10.32M	4.69M	15.8M	30.16M	14.52M	6.52M	2.99M
Cash & Short-Term Investments	91.34M	61.07M	33.32M	9.83M	3.74M	11.12M	29.21M	12.11M	5.9M	2.43M
Cash Only	66.69M	22.42M	19.19M	9.83M	3.74M	11.12M	29.21M	12.11M	5.9M	2.43M
Short-Term Investments	24.65M	38.66M	14.13M	0	0	0	0	0	0	0
Accounts Receivable	0	12.18K	10.38K	9.94K	0	3.86M	0	1.61M	0	0
Days Sales Outstanding	-	4.4	2.97	4.33	-	268.94	-	-	-	-
Inventory	0	454.13K	431.89K	186.92K	0	0	0	0	0	0
Days Inventory Outstanding	-	250.11	311.22	158.39	-	-	-	-	-	-
Other Current Assets	0	0	767.56K	249.09K	0	137.78K	172.99K	167.58K	151.27K	221.58K
Total Non-Current Assets+	2.82M	747.71K	457.63K	74.46K	9.2M	9.14M	10.67M	130.5K	66.85K	35.41K
Property, Plant & Equipment	382.44K	556.32K	331.04K	74K	25.02K	22.64K	7.88K	0	0	0
Fixed Asset Turnover	-	1.82x	3.85x	11.33x	138.51x	231.16x	-	-	-	-
Goodwill	0	0	0	0	8.87M	8.87M	8.87M	0	0	0
Intangible Assets	0	0	66.4K	0	0	0	0	0	0	0
Long-Term Investments	2.31M	0	0	0	0	0	1.61M	0	0	0
Other Non-Current Assets	126.83K	191.4K	60.2K	460	308.67K	247.11K	185.99K	130.5K	66.85K	35.41K
Total Assets+	95.07M	63.21M	34.99M	10.39M	13.89M	24.93M	40.83M	14.65M	6.59M	3.02M
Asset Turnover	-	0.02x	0.04x	0.08x	0.25x	0.21x	-	-	-	-
Asset Growth %	-	-0.34%	-0.45%	-0.7%	0.34%	0.79%	0.64%	-0.64%	-0.55%	-0.54%
Total Current Liabilities+	2.85M	3.89M	5.85M	5.02M	3.31M	2.77M	2.11M	4.27M	1.3M	1.51M
Accounts Payable	875.65K	1.19M	2M	342.53K	1.79M	1.85M	1.54M	2.86M	602.85K	936.99K
Days Payables Outstanding	6.41K	656.58	1.44K	290.25	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	502.33K	477.03K	0	0	289.64K	221.87K
Deferred Revenue (Current)	0	88K	72.19K	0	541.7K	0	0	0	0	0
Other Current Liabilities	672.51K	1.16M	2.9M	3.91M	317.76K	59.21K	0	0	0	0
Current Ratio	32.40x	16.06x	5.91x	2.06x	1.42x	5.70x	14.29x	3.40x	5.02x	1.98x
Quick Ratio	32.40x	15.94x	5.83x	2.02x	1.42x	5.70x	14.29x	3.40x	5.02x	1.98x
Cash Conversion Cycle	-	-402.07	-1.13K	-127.53	-	-	-	-	-	-
Total Non-Current Liabilities+	30.03K	8.4K	39.21K	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	30.03K	8.4K	39.21K	0	0	0	0	0	0	0
Total Liabilities	2.88M	3.9M	5.89M	1.11M	3.31M	2.77M	2.11M	4.27M	1.3M	1.51M
Total Debt+	0	0	0	0	502.33K	477.03K	0	0	289.64K	221.87K
Net Debt	-66.69M	-22.42M	-19.19M	-9.83M	-3.24M	-10.64M	-29.21M	-12.11M	-5.61M	-2.21M
Debt / Equity	-	-	-	-	0.05x	0.02x	-	-	0.05x	0.15x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-2555.41x	-	-	-	-
Total Equity+	92.19M	59.32M	29.11M	9.28M	10.58M	22.16M	38.72M	10.38M	5.29M	1.51M
Equity Growth %	-	-0.36%	-0.51%	-0.68%	0.14%	1.09%	0.75%	-0.73%	-0.49%	-0.71%
Book Value per Share	61286.57	54.54	25.17	7.69	9663.05	4246.01	2794.36	72.96	24.17	23.45
Total Shareholders' Equity	92.19M	59.32M	29.11M	9.28M	10.58M	22.16M	38.72M	10.38M	5.29M	1.51M
Common Stock	1.57K	1.68K	1.78K	1.81K	451	2.38K	4.52K	225	393	144
Retained Earnings	-37.15M	-76.65M	-111.08M	-132.96M	-12.08M	-19.43M	-32.2M	-63.81M	-76.35M	-81.92M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-24.65K	-1.61K	-1.25K	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-20.75M	-32.05M	-27.72M	-23.6M	-11.58M	-10.31M	-10.2M	-17.6M	-12.85M	-4.53M
Operating CF Margin %	-	-31.71%	-21.75%	-28.16%	-3.34%	-1.97%	-	-	-	-
Operating CF Growth %	-	-0.54%	0.14%	0.15%	0.51%	0.11%	0.01%	-0.72%	0.27%	0.65%
Net Income	-29.14M	-39.49M	-34.43M	-21.92M	-6.94M	-7.35M	-12.77M	-31.61M	-12.54M	-5.58M
Depreciation & Amortization	49.88K	277.23K	324.55K	228.16K	127.41K	18.06K	19.18K	6.68K	10.05K	4.42K
Stock-Based Compensation	6.6M	6.57M	4.22M	1.94M	751.62K	319.39K	559.04K	796.8K	524.84K	273.73K
Deferred Taxes	9.52K	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	4.12K	19.59K	-66.36K	31.85K	-1.31M	-258.55K	-44.69K	10.84M	130K	0
Working Capital Changes	1.73M	571.22K	2.23M	-3.88M	-4.21M	-3.04M	2.03M	2.37M	-968.33K	772.29K
Change in Receivables	0	0	1.8K	7.21K	690	-3.86M	2.25M	0	1.48M	0
Change in Inventory	0	0	22.24K	227.98K	1.17K	0	0	0	0	0
Change in Payables	621.39K	309.44K	819.36K	-1.66M	-519.28K	-2.78K	-310.66K	1.31M	-2.26M	334.14K
Cash from Investing+	-27.27M	-12.24M	24.49M	14.12M	5.61M	-2.6K	0	-1.5M	0	0
Capital Expenditures	-265.62K	-559.38K	-113.5K	0	0	-2.6K	0	0	-3	0
CapEx % of Revenue	-	0.55%	0.09%	-	-	0%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	5.25K	5.34K	4.8K	0	0	0	-1.5M	3	0
Cash from Financing+	80.84M	22.1K	2.63K	118.01K	3.58M	17.69M	28.3M	1.99M	6.64M	1.06M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	-133.59K	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	400K	0	0	118.01K	0	3.87M	1.49M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-21.01M	-32.61M	-27.84M	-23.6M	-11.58M	-10.31M	-10.2M	-19.1M	-12.85M	-4.53M
FCF Margin %	-	-32.27%	-21.84%	-28.16%	-3.34%	-1.97%	-	-	-	-
FCF Growth %	-	-0.55%	0.15%	0.15%	0.51%	0.11%	0.01%	-0.87%	0.33%	0.65%
FCF per Share	-13967.93	-29.98	-24.07	-19.55	-10575.61	-1976.30	-736.08	-134.15	-58.73	-70.20
FCF Conversion (FCF/Net Income)	0.71x	0.81x	0.81x	1.08x	1.67x	1.40x	0.80x	0.56x	1.02x	0.81x
Interest Paid	0	0	0	0	9.01K	8.66K	1.47K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.61%	-52.13%	-77.88%	-114.21%	-69.84%	-44.91%	-41.94%	-128.73%	-160.07%	-164.02%
Return on Invested Capital (ROIC)	-85.9%	-95.87%	-111.25%	-353.26%	-182.39%	-61.92%	-91.41%	-613.37%	-	-
Gross Margin	-	34.42%	60.26%	48.61%	100%	100%	-	-	-	-
Net Margin	-	-3907.65%	-2701.74%	-2615.57%	-200.18%	-140.49%	-	-	-	-
Debt / Equity	-	-	-	-	0.05x	0.02x	-	-	0.05x	0.15x
Interest Coverage	-	-	-	-	-	-2555.41x	-	-	-	-
FCF Conversion	0.71x	0.81x	0.81x	1.08x	1.67x	1.40x	0.80x	0.56x	1.02x	0.81x
Revenue Growth	-	-	26.11%	-34.24%	313.42%	51.03%	-100%	-	-	-

Revenue by Segment

	2016	2017	2018	2020
Grant, Castration-Resistant Prostate Study	-	-	-	2.6M
Grant, Castration-Resistant Prostate Study Growth	-	-	-	-
Product	-	-	826.51K	-
Product Growth	-	-	-	-
Product and Service, Other	-	-	11.63K	-
Product and Service, Other Growth	-	-	-	-
Consumer Operations	1.01M	1.27M	-	-
Consumer Operations Growth	-	26.11%	-	-
Drug Development	-	-	-	-
Drug Development Growth	-	-	-	-

Frequently Asked Questions

Growth & Financials

Salarius Pharmaceuticals, Inc. (SLRX) grew revenue by 0.0% over the past year. Growth has been modest.

Salarius Pharmaceuticals, Inc. (SLRX) reported a net loss of $5.0M for fiscal year 2024.

Dividend & Returns

Salarius Pharmaceuticals, Inc. (SLRX) has a return on equity (ROE) of -164.0%. Negative ROE indicates the company is unprofitable.

Salarius Pharmaceuticals, Inc. (SLRX) had negative free cash flow of $4.4M in fiscal year 2024, likely due to heavy capital investments.